Andrew S. Boyer - Jun 30, 2023 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role: Executive Vice President
Signature: /s/ Chris Daly, Attorney-in-Fact
Stock symbol: AMRX
Transactions as of: Jun 30, 2023
Transactions value $: -$35,870
Form type: 4
Date filed: 7/5/2023, 04:30 PM
Previous filing: Mar 7, 2023
Next filing: Aug 15, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMRX	Class A Common Stock	Options Exercise		+23.1K	+8.8%		286K	Jun 30, 2023	Direct	F1, F2
transaction	AMRX	Class A Common Stock	Tax liability	-$35.9K	-11.6K	-4.05%	$3.10	274K	Jun 30, 2023	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMRX	Restricted Stock Units	Options Exercise	$0	-23.1K	-100%	$0.00^*	0	Jun 30, 2023	Class A Common Stock	23.1K		Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the gross number of shares of Class A Common Stock, par value $0.01 per share (the "Class A Common Stock") issuable to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2	Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3	Represents shares of Class A Common Stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4	On August 1, 2020, the reporting person was granted 69,284 restricted stock units vesting in three equal installments beginning on June 30, 2021.